Literature DB >> 1427363

Chemotherapy for gastric cancer.

A Saini1, J Waxman.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1427363      PMCID: PMC1379475          DOI: 10.1136/gut.33.9.1153

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  10 in total

1.  A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin.

Authors:  S A Cullinan; C G Moertel; T R Fleming; J R Rubin; J E Krook; L K Everson; H E Windschitl; D I Twito; R F Marschke; J F Foley
Journal:  JAMA       Date:  1985-04-12       Impact factor: 56.272

2.  Sequential high-dose methotrexate and fluorouracil combined with doxorubicin--a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group.

Authors:  J A Wils; H O Klein; D J Wagener; H Bleiberg; H Reis; F Korsten; T Conroy; M Fickers; S Leyvraz; M Buyse
Journal:  J Clin Oncol       Date:  1991-05       Impact factor: 44.544

3.  A phase II study of combined 5-fluorouracil, doxorubicin, and cisplatin in the treatment of advanced upper gastrointestinal adenocarcinomas.

Authors:  C G Moertel; J Rubin; M J O'Connell; A J Schutt; H S Wieand
Journal:  J Clin Oncol       Date:  1986-07       Impact factor: 44.544

4.  An Eastern Cooperative Oncology Group evaluation of combinations of methyl-CCNU, mitomycin C, Adriamycin, and 5-fluorouracil in advanced measurable gastric cancer (EST 2277).

Authors:  H O Douglass; P T Lavin; A Goudsmit; D J Klaassen; A R Paul
Journal:  J Clin Oncol       Date:  1984-12       Impact factor: 44.544

5.  An EORTC Gastrointestinal Group evaluation of the combination of sequential methotrexate and 5-fluorouracil, combined with adriamycin in advanced measurable gastric cancer.

Authors:  J Wils; H Bleiberg; O Dalesio; G Blijham; N Mulder; A Planting; T Splinter; N Duez
Journal:  J Clin Oncol       Date:  1986-12       Impact factor: 44.544

6.  5-Fluorouracil, doxorubicin, and mitomycin (FAM) combination chemotherapy for advanced gastric cancer.

Authors:  J S MacDonald; P S Schein; P V Woolley; T Smythe; W Ueno; D Hoth; F Smith; M Boiron; C Gisselbrecht; R Brunet; C Lagarde
Journal:  Ann Intern Med       Date:  1980-10       Impact factor: 25.391

Review 7.  Chemotherapy of advanced gastric cancer: present status, future prospects.

Authors:  J S Macdonald; J J Gohmann
Journal:  Semin Oncol       Date:  1988-06       Impact factor: 4.929

8.  Preoperative chemotherapy in locally advanced and nonresectable gastric cancer: a phase II study with etoposide, doxorubicin, and cisplatin.

Authors:  H Wilke; P Preusser; U Fink; U Gunzer; H J Meyer; J Meyer; J R Siewert; W Achterrath; L Lenaz; H Knipp
Journal:  J Clin Oncol       Date:  1989-09       Impact factor: 44.544

9.  New developments in the treatment of gastric carcinoma.

Authors:  H Wilke; P Preusser; U Fink; W Achterrath; H J Meyer; M Stahl; L Lenaz; J Meyer; J R Siewert; H Geerlings
Journal:  Semin Oncol       Date:  1990-02       Impact factor: 4.929

10.  Enhanced 5-fluorouracil nucleotide formation after methotrexate administration: explanation for drug synergism.

Authors:  E Cadman; R Heimer; L Davis
Journal:  Science       Date:  1979-09-14       Impact factor: 47.728

  10 in total
  3 in total

1.  Helicobacter pylori and Epstein-Barr virus infection and the p53 tumour suppressor pathway in gastric stump cancer compared with carcinoma in the non-operated stomach.

Authors:  I O Baas; B P van Rees; A Musler; M E Craanen; G N Tytgat; F M van den Berg; G J Offerhaus
Journal:  J Clin Pathol       Date:  1998-09       Impact factor: 3.411

2.  Growth inhibition of human gastrointestinal cancer cells by cyclosporin A.

Authors:  M Piontek; R Porschen
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

3.  Adjuvant chemotherapy after gastric resection in node-positive cancer patients: a multicentre randomised study.

Authors:  B Neri; V de Leonardis; S Romano; F Andreoli; L M Pernice; L Bruno; D Borrelli; A Valeri; S Fabbroni; C Intini; G Cini
Journal:  Br J Cancer       Date:  1996-02       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.